{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:24:14Z","timestamp":1787862254541,"version":"build-2784847793"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110414","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T18:23:45Z","timestamp":1687976625000},"page":"110414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-1419","authenticated-orcid":false,"given":"Dehua","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dangang","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2023.110414_b0005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5694\/mja16.00586","article-title":"Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)","volume":"205","author":"Bourke","year":"2016","journal-title":"Med. J. Aust."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signaling"},{"issue":"9","key":"10.1016\/j.intimp.2023.110414_b0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110414_b0025","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.2147\/CMAR.S247554","article-title":"Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors","volume":"12","author":"Shimozaki","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"6","key":"10.1016\/j.intimp.2023.110414_b0030","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40259-016-0204-3","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors","volume":"30","author":"Day","year":"2016","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.intimp.2023.110414_b0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/annrheumdis-2017-212061","article-title":"The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy","volume":"77","author":"Calabrese","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2023.110414_b0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2023.110414_b0055","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with cancer immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2023.110414_b0065","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.intimp.2023.110414_b0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/1759-7714.12985","article-title":"Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis","volume":"10","author":"Deng","year":"2019","journal-title":"Thoracic cancer"},{"key":"10.1016\/j.intimp.2023.110414_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-5162-3","article-title":"Impact of diabetes mellitus on epithelial ovarian cancer survival","volume":"18","author":"Akhavan","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2023.110414_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0090","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database","volume":"69","author":"Bai","year":"2020","journal-title":"VigiBase, Endocrine"},{"key":"10.1016\/j.intimp.2023.110414_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109053","article-title":"Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data","volume":"110","author":"Zhu","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2023.110414_b0100","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor\u2013induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2023.110414_b0105","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"Case Reports"},{"issue":"26","key":"10.1016\/j.intimp.2023.110414_b0110","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy","volume":"10","author":"Baden","year":"2019","journal-title":"Diabetol. Int."},{"issue":"2","key":"10.1016\/j.intimp.2023.110414_b0120","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0125","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"11","key":"10.1016\/j.intimp.2023.110414_b0130","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor\u2013associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2023.110414_b0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"03","key":"10.1016\/j.intimp.2023.110414_b0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm. Metab. Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"10.1016\/j.intimp.2023.110414_b0150","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr. Connect."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.intimp.2023.110414_b0160","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s12272-010-1115-3","article-title":"Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes","volume":"33","author":"Won","year":"2010","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.intimp.2023.110414_b0165","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db07-1260","article-title":"Protective role of programmed death 1 ligand 1 (PD-L1) in nonobese diabetic mice: the paradox in transgenic models","volume":"57","author":"Wang","year":"2008","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clim.2007.05.013","article-title":"Mechanisms of PDL1-mediated regulation of autoimmune diabetes","volume":"125","author":"Guleria","year":"2007","journal-title":"Clin. Immunol."},{"issue":"416","key":"10.1016\/j.intimp.2023.110414_b0175","doi-asserted-by":"crossref","first-page":"eaam7543","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0180","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cmet.2017.01.005","article-title":"\u03b2 cells that resist immunological attack develop during progression of autoimmune diabetes in NOD mice","volume":"25","author":"Rui","year":"2017","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/aje\/kwi165","article-title":"CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE Review and meta-analysis","volume":"162","author":"Kavvoura","year":"2005","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110414_b0190","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1399-0039.2003.00136.x","article-title":"Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes","volume":"62","author":"Nielsen","year":"2003","journal-title":"Tissue Antigens"},{"issue":"2","key":"10.1016\/j.intimp.2023.110414_b0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00439-006-0309-8","article-title":"PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children","volume":"121","author":"Ni","year":"2007","journal-title":"Hum. Genet."},{"key":"10.1016\/j.intimp.2023.110414_b0200","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1614683","article-title":"Association of PD-1 and PD-L1 genetic polymorphyisms with type 1 diabetes susceptibility","volume":"2018","author":"Qian","year":"2018","journal-title":"Journal of diabetes research"},{"issue":"7","key":"10.1016\/j.intimp.2023.110414_b0205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/imt-2017-0020","article-title":"A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient","volume":"9","author":"Ara\u00fajo","year":"2017","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2023.110414_b0215","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/dme.13762","article-title":"Diabetes associated with immune checkpoint inhibition: presentation and management challenges","volume":"35","author":"Galligan","year":"2018","journal-title":"Diabet. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0220","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jdermsci.2020.01.011","article-title":"Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer","volume":"97","author":"Yu","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2023.110414_b0225","first-page":"EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","author":"Arima","year":"2019","journal-title":"Endocr. J."},{"issue":"4","key":"10.1016\/j.intimp.2023.110414_b0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13340-012-0098-3","article-title":"Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa","year":"2012","journal-title":"Diabetol. Int."},{"issue":"8","key":"10.1016\/j.intimp.2023.110414_b0235","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/dmrr.1236","article-title":"Fulminant type 1 diabetes\u2014an important subtype in East Asia","volume":"27","author":"Imagawa","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2023.110414_b0240","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0245","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0897190019850929","article-title":"Programmed cell death-1 monoclonal antibody therapy and type 1 diabetes mellitus: a review of the literature","volume":"34","author":"Farina","year":"2021","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.intimp.2023.110414_b0255","doi-asserted-by":"crossref","unstructured":"I. Puzanov, A. Diab, K. Abdallah, C.r. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. Lacouture, N. LeBoeuf, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J. Immunotherapy Cancer 5(1) (2017) 1-28.","DOI":"10.1186\/s40425-017-0300-z"},{"key":"10.1016\/j.intimp.2023.110414_b0260","doi-asserted-by":"crossref","unstructured":"J. Haanen, F. Carbonnel, C. Robert, K. Kerr, S. Peters, J. Larkin, K. Jordan, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of oncology 28 (2017) iv119-iv142.","DOI":"10.1093\/annonc\/mdx225"},{"issue":"5","key":"10.1016\/j.intimp.2023.110414_b0265","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.intimp.2023.110414_b0270","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/nano10040789","article-title":"Emerging nano-and micro-technologies used in the treatment of type-1 diabetes","volume":"10","author":"Primavera","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.intimp.2023.110414_b0275","doi-asserted-by":"crossref","unstructured":"R. Primavera, M. Magnone, D.D. Mascolo, E. Zocchi, A.D. Pascale, P. Decuzzi, Controlled Release of Insulin Granules from PLGA Microparticles for Glucose Modulation in Diabetes, Diabetes 67(Supplement_1) (2018).","DOI":"10.2337\/db18-2279-PUB"},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0280","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejpb.2010.09.016","article-title":"Preparation and evaluation of alginate\u2013chitosan microspheres for oral delivery of insulin","volume":"77","author":"Zhang","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.intimp.2023.110414_b0285","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2337\/db14-0656","article-title":"Preserved \u03b2-cell function in type 1 diabetes by mesenchymal stromal cells","volume":"64","author":"Carlsson","year":"2015","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.intimp.2023.110414_b0290","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3727\/096368913X665576","article-title":"Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study","volume":"23","author":"Bhansali","year":"2014","journal-title":"Cell Transplant."},{"issue":"6","key":"10.1016\/j.intimp.2023.110414_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-021-01384-6","article-title":"The role of programmed death-1 in type 1 diabetes","volume":"21","author":"Tucker","year":"2021","journal-title":"Curr. Diab. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2023.110414_b0300","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","article-title":"Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases","volume":"14","author":"Shi","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110414_b0305","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/CIRCRESAHA.109.210682","article-title":"Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice","volume":"106","author":"Chimenti","year":"2010","journal-title":"Circ. Res."},{"issue":"7","key":"10.1016\/j.intimp.2023.110414_b0310","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00125-009-1374-z","article-title":"Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells","volume":"52","author":"Madec","year":"2009","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.intimp.2023.110414_b0315","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00125-022-05708-3","article-title":"Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade","volume":"65","author":"Kawada-Horitani","year":"2022","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.intimp.2023.110414_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-017-0877-0","article-title":"Islet microencapsulation: strategies and clinical status in diabetes","volume":"17","author":"Omami","year":"2017","journal-title":"Curr. Diab. Rep."},{"issue":"7\u20138","key":"10.1016\/j.intimp.2023.110414_b0325","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.addr.2010.01.005","article-title":"Bioartificial pancreas: Microencapsulation and conformal coating of islet of Langerhans","volume":"62","author":"Teramura","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.intimp.2023.110414_b0330","doi-asserted-by":"crossref","first-page":"1900423","DOI":"10.1002\/adhm.201900423","article-title":"Interconnected toroidal hydrogels for islet encapsulation","volume":"8","author":"Ernst","year":"2019","journal-title":"Adv. Healthc. Mater."},{"issue":"20","key":"10.1016\/j.intimp.2023.110414_b0335","doi-asserted-by":"crossref","first-page":"eabd5835","DOI":"10.1126\/sciadv.abd5835","article-title":"An inverse-breathing encapsulation system for cell delivery","volume":"7","author":"Wang","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-52768-7","article-title":"A bioinspired scaffold for rapid oxygenation of cell encapsulation systems","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.110414_b0345","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2019.01.013","article-title":"Nanotechnology in cell replacement therapies for type 1 diabetes","volume":"139","author":"Ernst","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2023.110414_b0350","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MOT.0000000000000270","article-title":"Novel technologies to engineer graft for tolerance induction","volume":"21","author":"Woodward","year":"2016","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"4472","key":"10.1016\/j.intimp.2023.110414_b0355","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1126\/science.6776628","article-title":"Microencapsulated islets as bioartificial endocrine pancreas","volume":"210","author":"Lim","year":"1980","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.intimp.2023.110414_b0360","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.3727\/096368915X686184","article-title":"Surface coating of pancreatic islets with neural crest stem cells improves engraftment and function after intraportal transplantation","volume":"24","author":"Lau","year":"2015","journal-title":"Cell Transplant."},{"issue":"3","key":"10.1016\/j.intimp.2023.110414_b0365","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ajt.14547","article-title":"Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol","volume":"18","author":"Manzoli","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2023.110414_b0370","doi-asserted-by":"crossref","unstructured":"S. Song, Silicon Nanopore Membrane (SNM) for Islet Encapsulation Under Convective Transport to Treat Type 1 Diabetes (T1D), University of California, San Francisco2016.","DOI":"10.1038\/srep23679"},{"issue":"18","key":"10.1016\/j.intimp.2023.110414_b0375","doi-asserted-by":"crossref","first-page":"11458","DOI":"10.1021\/acs.chemrev.0c01062","article-title":"Hydrogels in emerging technologies for type 1 diabetes","volume":"121","author":"Fuchs","year":"2020","journal-title":"Chem. Rev."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:12:27Z","timestamp":1736431947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923007373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":75,"alternative-id":["S1567576923007373"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110414","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110414"}}